Key Highlights: Implications: For Novartis India, bringing these brands back in‑house supports a more controlled go‑to‑market under new PE ownership and aligns with its plan to insta...
Key Highlights: Implications: The new cGMP/US FDA/EU-compliant suite at Gland’s Visakhapatnam JNPC site, adding ~1,400 kg/year of sterile API capacity, should help both companies capture m...
Key Highlights: Implications: Poviztra’s new MASH label lets Emcure plug innovator semaglutide directly into India’s emerging fatty liver treatment market, riding on ESSENCE data (63% stea...
Key Highlights: Implications: RPG Life Sciences is launching India’s first fixed-dose Naproxen + Esomeprazole tablet, Naprosyn ES, to enable safer long-term NSAID use by adding gastroprote...
Key Highlights: Implications: Mankind Pharma’s AI-led drug discovery partnership with Denovo Sciences strengthens its innovation agenda and adds another serious player to India’s eme...
